393 related articles for article (PubMed ID: 31286691)
41. Establishment and characterization of a novel murine model of pancreatic cancer cachexia.
Michaelis KA; Zhu X; Burfeind KG; Krasnow SM; Levasseur PR; Morgan TK; Marks DL
J Cachexia Sarcopenia Muscle; 2017 Oct; 8(5):824-838. PubMed ID: 28730707
[TBL] [Abstract][Full Text] [Related]
42. Concomitant over-expression of activin/inhibin beta subunits and their receptors in human pancreatic cancer.
Kleeff J; Ishiwata T; Friess H; Büchler MW; Korc M
Int J Cancer; 1998 Sep; 77(6):860-8. PubMed ID: 9714055
[TBL] [Abstract][Full Text] [Related]
43. The histone deacetylase SIRT6 blocks myostatin expression and development of muscle atrophy.
Samant SA; Kanwal A; Pillai VB; Bao R; Gupta MP
Sci Rep; 2017 Sep; 7(1):11877. PubMed ID: 28928419
[TBL] [Abstract][Full Text] [Related]
44. Phases of Metabolic and Soft Tissue Changes in Months Preceding a Diagnosis of Pancreatic Ductal Adenocarcinoma.
Sah RP; Sharma A; Nagpal S; Patlolla SH; Sharma A; Kandlakunta H; Anani V; Angom RS; Kamboj AK; Ahmed N; Mohapatra S; Vivekanandhan S; Philbrick KA; Weston A; Takahashi N; Kirkland J; Javeed N; Matveyenko A; Levy MJ; Mukhopadhyay D; Chari ST
Gastroenterology; 2019 May; 156(6):1742-1752. PubMed ID: 30677401
[TBL] [Abstract][Full Text] [Related]
45. Inflammation and Wasting of Skeletal Muscles in Kras-p53-Mutant Mice with Intraepithelial Neoplasia and Pancreatic Cancer-When Does Cachexia Start?
Hildebrandt W; Keck J; Schmich S; Bonaterra GA; Wilhelm B; Schwarzbach H; Eva A; Bertoune M; Slater EP; Fendrich V; Kinscherf R
Cells; 2022 May; 11(10):. PubMed ID: 35626644
[TBL] [Abstract][Full Text] [Related]
46. Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy.
Morvan F; Rondeau JM; Zou C; Minetti G; Scheufler C; Scharenberg M; Jacobi C; Brebbia P; Ritter V; Toussaint G; Koelbing C; Leber X; Schilb A; Witte F; Lehmann S; Koch E; Geisse S; Glass DJ; Lach-Trifilieff E
Proc Natl Acad Sci U S A; 2017 Nov; 114(47):12448-12453. PubMed ID: 29109273
[TBL] [Abstract][Full Text] [Related]
47. Elevated serum Activin A in chronic obstructive pulmonary disease with skeletal muscle wasting.
Zhou G; Gui X; Chen R; Fu X; Ji X; Ding H
Clinics (Sao Paulo); 2019; 74():e981. PubMed ID: 31271588
[TBL] [Abstract][Full Text] [Related]
48. Increased myocellular lipid and IGFBP-3 expression in a pre-clinical model of pancreatic cancer-related skeletal muscle wasting.
Cole CL; Bachman JF; Ye J; Murphy J; Gerber SA; Beck CA; Boyce BF; Muthukrishnan G; Chakkalakal JV; Schwarz EM; Linehan D
J Cachexia Sarcopenia Muscle; 2021 Jun; 12(3):731-745. PubMed ID: 33960737
[TBL] [Abstract][Full Text] [Related]
49. Mas Receptor Activation Slows Tumor Growth and Attenuates Muscle Wasting in Cancer.
Murphy KT; Hossain MI; Swiderski K; Chee A; Naim T; Trieu J; Haynes V; Read SJ; Stapleton DI; Judge SM; Trevino JG; Judge AR; Lynch GS
Cancer Res; 2019 Feb; 79(4):706-719. PubMed ID: 30420474
[TBL] [Abstract][Full Text] [Related]
50. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival.
Zhou X; Wang JL; Lu J; Song Y; Kwak KS; Jiao Q; Rosenfeld R; Chen Q; Boone T; Simonet WS; Lacey DL; Goldberg AL; Han HQ
Cell; 2010 Aug; 142(4):531-43. PubMed ID: 20723755
[TBL] [Abstract][Full Text] [Related]
51. C/EBPβ promotes the expression of atrophy-inducing factors by tumours and is a central regulator of cancer cachexia.
AlSudais H; Rajgara R; Saleh A; Wiper-Bergeron N
J Cachexia Sarcopenia Muscle; 2022 Feb; 13(1):743-757. PubMed ID: 35014202
[TBL] [Abstract][Full Text] [Related]
52. Prevention of cachexia-like syndrome development and reduction of tumor progression in inhibin-deficient mice following administration of a chimeric activin receptor type II-murine Fc protein.
Li Q; Kumar R; Underwood K; O'Connor AE; Loveland KL; Seehra JS; Matzuk MM
Mol Hum Reprod; 2007 Sep; 13(9):675-83. PubMed ID: 17704537
[TBL] [Abstract][Full Text] [Related]
53. Clinical significance of activin A and myostatin in patients with pancreatic adenocarcinoma and progressive weight loss.
Talar-Wojnarowska R; Wozniak M; Borkowska A; Olakowski M; Malecka-Panas E
J Physiol Pharmacol; 2020 Feb; 71(1):. PubMed ID: 32554845
[TBL] [Abstract][Full Text] [Related]
54. ZIP4 Promotes Muscle Wasting and Cachexia in Mice With Orthotopic Pancreatic Tumors by Stimulating RAB27B-Regulated Release of Extracellular Vesicles From Cancer Cells.
Yang J; Zhang Z; Zhang Y; Ni X; Zhang G; Cui X; Liu M; Xu C; Zhang Q; Zhu H; Yan J; Zhu VF; Luo Y; Hagan JP; Li Z; Fang J; Jatoi A; Fernandez-Zapico ME; Zheng L; Edil BH; Bronze MS; Houchen CW; Li YP; Li M
Gastroenterology; 2019 Feb; 156(3):722-734.e6. PubMed ID: 30342032
[TBL] [Abstract][Full Text] [Related]
55. Twist1 Activation in Muscle Progenitor Cells Causes Muscle Loss Akin to Cancer Cachexia.
Parajuli P; Kumar S; Loumaye A; Singh P; Eragamreddy S; Nguyen TL; Ozkan S; Razzaque MS; Prunier C; Thissen JP; Atfi A
Dev Cell; 2018 Jun; 45(6):712-725.e6. PubMed ID: 29920276
[TBL] [Abstract][Full Text] [Related]
56. Targeting myostatin/activin A protects against skeletal muscle and bone loss during spaceflight.
Lee SJ; Lehar A; Meir JU; Koch C; Morgan A; Warren LE; Rydzik R; Youngstrom DW; Chandok H; George J; Gogain J; Michaud M; Stoklasek TA; Liu Y; Germain-Lee EL
Proc Natl Acad Sci U S A; 2020 Sep; 117(38):23942-23951. PubMed ID: 32900939
[TBL] [Abstract][Full Text] [Related]
57. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer.
Mace TA; Shakya R; Pitarresi JR; Swanson B; McQuinn CW; Loftus S; Nordquist E; Cruz-Monserrate Z; Yu L; Young G; Zhong X; Zimmers TA; Ostrowski MC; Ludwig T; Bloomston M; Bekaii-Saab T; Lesinski GB
Gut; 2018 Feb; 67(2):320-332. PubMed ID: 27797936
[TBL] [Abstract][Full Text] [Related]
58. Differential Effects of IL6 and Activin A in the Development of Cancer-Associated Cachexia.
Chen JL; Walton KL; Qian H; Colgan TD; Hagg A; Watt MJ; Harrison CA; Gregorevic P
Cancer Res; 2016 Sep; 76(18):5372-82. PubMed ID: 27328730
[TBL] [Abstract][Full Text] [Related]
59. ACVR2B/Fc counteracts chemotherapy-induced loss of muscle and bone mass.
Barreto R; Kitase Y; Matsumoto T; Pin F; Colston KC; Couch KE; O'Connell TM; Couch ME; Bonewald LF; Bonetto A
Sci Rep; 2017 Oct; 7(1):14470. PubMed ID: 29089584
[TBL] [Abstract][Full Text] [Related]
60. Lcn2 mediates adipocyte-muscle-tumor communication and hypothermia in pancreatic cancer cachexia.
Lemecha M; Chalise JP; Takamuku Y; Zhang G; Yamakawa T; Larson G; Itakura K
Mol Metab; 2022 Dec; 66():101612. PubMed ID: 36243318
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
